Tradestie Institutional Equity Comparison Engine

RBOT.WS vs ZBH โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBH Overall Edge

ZBH Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zimmer Biomet Holdings, Inc. (ZBH) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RBOT.WS trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ZBH at 11.3x Forward P/E and 16.7% operating margin (+3.1% YoY). In options structure, RBOT.WS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ZBH sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ZBH
RBOT.WS N/M vs ZBH 11.3x Fwd P/E
Growth & Margin Winner ZBH
Op Margin N/A vs 16.7% ยท YoY N/A vs +3.1%
Momentum & Technical Winner ZBH
1Y -67.2% vs +13.0% ยท 52W Pos 0% vs 66%
Options & Structure Winner ZBH
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (100th %ile IV)
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
1M Return -67.2%
1Y Return -67.2%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
ZBH NYSE
Zimmer Biomet Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$101.10
-0.36% 1D
Market Cap $19.2B
1M Return +2.32%
1Y Return +13.02%
Forward P/E 11.3x
Unified AI Score
46.6 / 100 HOLD
Tech 36.0 Fund 48.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RBOT.WS -67.2% ZBH +13.02% Spread: +70.93 pp (ZBH Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RBOT.WS TTM Op. Margin: N/A ZBH TTM Op. Margin: 16.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs ZBH. Trailing 12-month operating profitability (RBOT.WS N/A vs ZBH 16.7%) and valuation multiples (RBOT.WS N/M vs ZBH 11.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RBOT.WS (1) vs ZBH (9)
Institutional Metric RBOT.WS ZBH Criterion Row Winner
Market Capitalization Scale N/A $19.2B Larger Scale ZBH
Trailing P/E Ratio Valuation N/M 25.6x Lower Multiple ZBH
Forward P/E Ratio Valuation N/M 11.3x Lower Multiple ZBH
Revenue Growth (YoY) Growth N/A +3.1% Higher Growth ZBH
Operating Margin (TTM) Profitability N/A 16.7% Higher Margin ZBH
Net Profit Margin Profitability N/A 8.9% Higher Margin ZBH
Return on Equity (ROE) Capital Efficiency N/A 6.0% Higher ROE ZBH
52-Week Range Position Momentum 0% ($0โ€“$0) 66% ($79โ€“$113) Stronger Trend ZBH
Beta / 30D Volatility Risk Regime N/A 0.40ฮฒ ยท 54% Vol Lower Realized Risk ZBH
Unified Institutional Score Composite Signal 50.1 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite RBOT.WS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RBOT.WS vs ZBH Buy Guide
RBOT.WS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RBOT.WS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live ZBH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RBOT.WS nor ZBH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.